SCHEDULE: Venrock Healthcare Group Discloses 8.2% Stake in DBV Technologies

Venrock Healthcare Capital Partners and its affiliates have reported a collective 8.2% beneficial ownership stake in DBV Technologies S.A., totaling 11,929,079 ordinary shares.

Summary

• Venrock Healthcare Capital Partners II, L.P., along with several affiliated entities and individuals Nimish Shah and Bong Koh (collectively, the "Reporting Persons"), filed an Amendment No. 4 to Schedule 13G.
• The Reporting Persons collectively beneficially own 11,929,079 ordinary shares of DBV Technologies S.A.
• This ownership represents 8.2% of the issuer's ordinary shares outstanding as of September 30, 2025.
• The percentage is calculated based on 136,975,159 ordinary shares outstanding and 9,150,000 ordinary shares issuable upon the exercise of Pre-Funded Warrants, as reported in DBV Technologies' Quarterly Report on Form 10-Q filed on October 28, 2025.
• The ownership includes both directly held ordinary shares and Pre-Funded Warrants exercisable into ordinary shares.
• The Reporting Persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant beneficial ownership stake by an institutional investor group. While neutral in itself, the continued holding of a substantial position by a healthcare-focused fund can be interpreted as a moderately positive signal of confidence in the underlying company, DBV Technologies. There are no explicit positive or negative operational details within the filing.

Positives

• A significant institutional investor group, Venrock Healthcare Capital Partners, maintains a substantial 8.2% stake in DBV Technologies, indicating continued confidence in the company.
• The filing provides transparency regarding the beneficial ownership structure of a major institutional holder.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investor interest in DBV Technologies, a biotechnology company. Large stakes by healthcare-focused funds like Venrock can signal long-term investment theses in the sector, particularly for companies in the clinical development or commercialization phases.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder's stake, which can influence investor perception and potentially market liquidity. The continued holding of a substantial position by a specialized healthcare fund may be viewed positively.
• Management: Awareness of a large, stable institutional shareholder group can influence strategic decisions and corporate governance discussions.

Key Dates

Recommendation

This Schedule 13G/A filing is a routine disclosure of beneficial ownership by Venrock Healthcare Capital Partners and its affiliates in DBV Technologies. It confirms a continued significant stake of 8.2% as of September 30, 2025. As an amendment, it primarily updates the public record on an existing position rather than signaling a new investment thesis or a material change in the investor's stance. There are no new operational, financial, or strategic details about DBV Technologies within this filing that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's fundamentals and broader market conditions, which are not addressed in this specific filing.

Keywords

DBV Technologies, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals, Ordinary Shares, Pre-Funded Warrants, SEC Filing